WO2008041914A1 - DÉRIVÉS DE LA 5-(2-AMINO-1-HYDROXYÉTHYL)-8-HYDROXY-2-OXOQUINOLÉINE ET AUTRES COMPOSÉS EN TANT QU'AGONISTES β2-ADRÉNERGIQUES - Google Patents

DÉRIVÉS DE LA 5-(2-AMINO-1-HYDROXYÉTHYL)-8-HYDROXY-2-OXOQUINOLÉINE ET AUTRES COMPOSÉS EN TANT QU'AGONISTES β2-ADRÉNERGIQUES Download PDF

Info

Publication number
WO2008041914A1
WO2008041914A1 PCT/SE2007/000885 SE2007000885W WO2008041914A1 WO 2008041914 A1 WO2008041914 A1 WO 2008041914A1 SE 2007000885 W SE2007000885 W SE 2007000885W WO 2008041914 A1 WO2008041914 A1 WO 2008041914A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/SE2007/000885
Other languages
English (en)
Inventor
Lilian Alcaraz
Stephen Connolly
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of WO2008041914A1 publication Critical patent/WO2008041914A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dérivés de la 5-(2-amino-1-hydroxyéthyl)-8-hydroxy-2-oxoquinoléine et d'autres composés de formule (I) dans laquelle R1 est, où R4, R5 et M1 sont tels que définis dans la description, ou bien R1 est tel que défini dans la description et dans laquelle R2, R3, W, A, X et Y sont tels que définis dans la description; des procédés pour la préparation de ceux-ci; des compositions pharmaceutiques contenant ceux-ci et l'utilisation de ceux-ci dans le traitement de maladies ou affections dans lesquelles la modulation de l'activité des récepteurs β2-adrénergiques est bénéfique, par exemple le syndrome de détresse respiratoire de l'adulte (SDRA), l'emphysème pulmonaire, la bronchite, la bronchiectasie, la bronchopneumopathie chronique obstructive (BPCO), l'asthme ou la rhinite. Les composés sont des agonistes β2-adrénergiques.
PCT/SE2007/000885 2006-10-06 2007-10-05 DÉRIVÉS DE LA 5-(2-AMINO-1-HYDROXYÉTHYL)-8-HYDROXY-2-OXOQUINOLÉINE ET AUTRES COMPOSÉS EN TANT QU'AGONISTES β2-ADRÉNERGIQUES WO2008041914A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82839006P 2006-10-06 2006-10-06
US60/828,390 2006-10-06

Publications (1)

Publication Number Publication Date
WO2008041914A1 true WO2008041914A1 (fr) 2008-04-10

Family

ID=39268691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2007/000885 WO2008041914A1 (fr) 2006-10-06 2007-10-05 DÉRIVÉS DE LA 5-(2-AMINO-1-HYDROXYÉTHYL)-8-HYDROXY-2-OXOQUINOLÉINE ET AUTRES COMPOSÉS EN TANT QU'AGONISTES β2-ADRÉNERGIQUES

Country Status (1)

Country Link
WO (1) WO2008041914A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700782B2 (en) 2006-12-20 2010-04-20 Astrazeneca Ab Compounds 569
US7709511B2 (en) 2005-08-09 2010-05-04 Astrazeneca Ab Benzothiazolone derivatives
US7951954B2 (en) 2006-03-14 2011-05-31 Astrazeneca Ab Bezothiazol derivatives as Beta2 adrenoreceptor agonists
US8017602B2 (en) 2008-06-18 2011-09-13 Astrazeneca Ab N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
US8058294B2 (en) 2007-02-08 2011-11-15 Astrazeneca Ab Pharmaceutical salts of N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-napthyl)ethoxy]propanamide
CN107961235A (zh) * 2017-12-27 2018-04-27 湖北工业大学 芳香酯化合物wy124用于制备抗adv-7病毒的药物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162576A1 (fr) * 1984-04-17 1985-11-27 Glaxo Group Limited Composés d'éthanolamine
EP0220878A2 (fr) * 1985-10-16 1987-05-06 Glaxo Group Limited Composés d'éthanolamine
WO2002076933A1 (fr) * 2001-03-22 2002-10-03 Glaxo Group Limited Derives formanilides utilises en tant qu'agonistes de l'adrenorecepteur beta2
WO2004016578A2 (fr) * 2002-07-25 2004-02-26 Glaxo Group Limited Composes medicamenteux
WO2005121065A2 (fr) * 2004-06-03 2005-12-22 Theravance, Inc. Agonistes des recepteurs $g(b)2-adrenergiques diaminiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162576A1 (fr) * 1984-04-17 1985-11-27 Glaxo Group Limited Composés d'éthanolamine
EP0220878A2 (fr) * 1985-10-16 1987-05-06 Glaxo Group Limited Composés d'éthanolamine
WO2002076933A1 (fr) * 2001-03-22 2002-10-03 Glaxo Group Limited Derives formanilides utilises en tant qu'agonistes de l'adrenorecepteur beta2
WO2004016578A2 (fr) * 2002-07-25 2004-02-26 Glaxo Group Limited Composes medicamenteux
WO2005121065A2 (fr) * 2004-06-03 2005-12-22 Theravance, Inc. Agonistes des recepteurs $g(b)2-adrenergiques diaminiques

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709511B2 (en) 2005-08-09 2010-05-04 Astrazeneca Ab Benzothiazolone derivatives
US7951954B2 (en) 2006-03-14 2011-05-31 Astrazeneca Ab Bezothiazol derivatives as Beta2 adrenoreceptor agonists
US7700782B2 (en) 2006-12-20 2010-04-20 Astrazeneca Ab Compounds 569
US8058294B2 (en) 2007-02-08 2011-11-15 Astrazeneca Ab Pharmaceutical salts of N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-napthyl)ethoxy]propanamide
US8017602B2 (en) 2008-06-18 2011-09-13 Astrazeneca Ab N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
CN107961235A (zh) * 2017-12-27 2018-04-27 湖北工业大学 芳香酯化合物wy124用于制备抗adv-7病毒的药物
CN107961235B (zh) * 2017-12-27 2019-09-24 湖北工业大学 芳香酯化合物wy124用于制备抗adv-7病毒的药物

Similar Documents

Publication Publication Date Title
CA2618511C (fr) Derives innovants de benzothiazolone
US20090221653A1 (en) 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists
EP2121642B1 (fr) Composés 4-hydroxy-2-oxo-2, 3 -dihydro- 1, 3-benzothiazol-7-yl pour la modulation de l'activité de b2-adrénorécepteur
US7951954B2 (en) Bezothiazol derivatives as Beta2 adrenoreceptor agonists
US20090203753A1 (en) 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists
AU2007336074B2 (en) Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases
WO2008104790A1 (fr) Sels d'un agoniste de l'adrénorécepteur bêta-2 sélectif
AU2008212714A1 (en) Salts 668
WO2009154557A1 (fr) Dérivés de benzoxazinone agissant comme agoniste des récepteurs bêta2-adrénergiques pour le traitement de troubles respiratoires
WO2011048409A1 (fr) Dérivés d'amine cyclique ayant une activité agoniste de récepteur adrénergique bêta-2 et antagoniste de récepteur muscarinique
WO2008041914A1 (fr) DÉRIVÉS DE LA 5-(2-AMINO-1-HYDROXYÉTHYL)-8-HYDROXY-2-OXOQUINOLÉINE ET AUTRES COMPOSÉS EN TANT QU'AGONISTES β2-ADRÉNERGIQUES
WO2011154678A1 (fr) Composés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07835087

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07835087

Country of ref document: EP

Kind code of ref document: A1